ALT Page 1 of FDNA's press release. Headline: FDNA Selected by ARPA-H to Help Families Reach a Rare Disease Diagnosis Sooner. Dated Atlanta, August 31, 2026. FDNA has been selected as a performer in ARPA-H's Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) program. The release describes how Family Health Checker gives parents a digital front door to bring concerns, photos, symptoms and health history into a clinical workflow, and how Face2Gene helps clinicians develop a differential list of possible syndromic conditions, with diagnosis remaining a clinical determination. It closes with a quote from CEO and Co-Founder Erik A. Feingold: Families shouldn't need to understand the rare disease system before the system can help them.

ALT Page 2 of FDNA's press release. Section About ARPA-H RAPID: RAPID is led by program manager Scott Gorman in ARPA-H's Proactive Health Office. More than 10,000 rare diseases affect over 350 million people worldwide, and the diagnostic odyssey takes six years on average. RAPID is a 4.5-year program to build a large rare disease dataset and develop AI tools. Section About FDNA: headquartered in Atlanta, develops computer vision and AI-powered phenotyping and differential decision-support technologies. Face2Gene is used across more than 10,000 clinical sites in over 130 countries. Family Health Checker is non-diagnostic. Includes an ARPA-H funding disclaimer and media contact details for Stefanie Eichner.

ALT FDNA graphic for Plasminogen Deficiency Awareness Day noting that PLGD-1 is often mistaken for chronic pink eye, recurring ear infections, or a persistent cough, and that earlier recognition matters.